PROCEPT BioRobotics (PRCT) investor relations material

Market opportunity and growth strategy

• Approximately 40 million U.S. men live with BPH, with only a fraction receiving surgical intervention annually.

• Aquablation has achieved over 125,000 patients treated worldwide and a global install base exceeding 970 systems.

• Aquablation is trending toward becoming the leading modern surgical BPH treatment, closing the gap with TURP.

• Category I reimbursement for Aquablation in the U.S. is effective January 2026, supporting its move to standard of care.

• The company is expanding access through greenfield placements, targeted replacements, and leasing pilots.

Clinical differentiation and patient outcomes

• Aquablation offers a complete solution for BPH across all prostate sizes, prioritizing symptom relief and preservation of sexual and urinary function.

• Patients value risk reduction for bladder control and erectile dysfunction, as well as minimizing the need for repeat procedures.

• Aquablation demonstrates high re-operation-free rates compared to other BPH procedures.

• Clinical evidence supports Aquablation as a frontline option for both BPH and, potentially, prostate cancer.

Organizational and commercial initiatives

• Realignment of the commercial organization enables single-point accountability and focus on procedure growth at the regional level.

• Dedicated launch teams standardize training, reimbursement, and patient education, reducing time to first cases by about 50% in pilot accounts.

• Expansion strategies include greenfield placements, targeted replacements, and leasing pilots to reach more customers.